All episodes
Examining the State of Sleep
TheStreet’s Adam Feuerstein Previews ASCO 2015
Home-Brew Morphine, Dual Use Technology, and the Biologist’s Repsonsibilities
Reinventing Tech Transfer
Thinking Narrowly About Antibiotics
Promise Shown in Different Approach to Alzheimer’s
Innovative Drugs Drive Big Increase in U.S. Spending
Ensuring Digital Health Technologies Benefit Older People
How the Sugar Industry Influenced Research to Protect Its Interests
Examining The White House’s Plan to Combat Drug-Resistant Bacteria
Weighing Adverse Events to Get at a Drug’s Real Costs
How One Company Is Reinventing Drug Development
Why Patent Trolling Threatens Biopharma
Shifting Venture Investment Raises Concerns
Will Policy Triumph Over Politics in 21st Century Cures Act
Democratizing the World of Healthcare Analytics
Will Funding for Obama’s Precision Medicine Initiative Match Its Ambition
Should Investors Temper Their Enthusiasm for CAR-T Therapies
What to Do About the United States’ Declining Investment in R&D
Why Big Pharma Hasn’t Been Able to Fix Its Revenue Gap with M&A
Remembering Industry Pioneer Ron Cape
Moving from Chronic Therapies to Cures
What’s in Store for the Biotech Industry in 2015
A Look at the Year That Was in Biotech
Why Privacy Concerns May Limit Big Data’s Payoff
Calculating the Cost of Drug Development and What it Means
How New Funding Models Are Accelerating Drug Development
Telemedicine Grows, but Reimbursement Remains an Obstacle
The Power of IBM’s Watson Is Coming to an App Near You
Brittany Maynard and the Debate over the Right to Die
What’s Driving the Booming Market for Orphan Drugs
Why Interoperability Is Much More than a Technology Problem
The Lean Startup Takes Hold in the Life Sciences
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance
The Forces Bringing Disruptive Change to Healthcare
How One Foundation is Getting the Biggest Bang for Its R&D Bucks
International Collaboration Seeks to Drive Breakthroughs in Progressive MS
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine
Using Human Biology to Improve R&D
Reengineering Drug Discovery and Development
The Year in Biotech So Far and What’s Ahead
Epirus Sees Opportunities for Biosimilars Outside U.S.